Human Neutrophil Gelatinase-Associated Lipocalin: A New Biomarker in Asthma-COPD Overlap Syndrome

Le résumé fourni par la source

Abstract AIM Human neutrophil gelatinase-associated lipocalin (NGAL) is a protein considered as a noninvasive prognostic biomarker in Asthma-COPD overlap syndrome (ACO). In this study we aimed to show the usability of NGAL as a biomarker in ACO characterized with airway inflammation. MATERIAL-METHOD: Three patient groups (Group I: COPD, n: 50, Group II: Asthma, n:50, Group III: ACO, n:50) and a healhty non smoker group (Group IV, n:50) are taken into study. The serum NGAL levels of groups are compared. In addition, in Group I,II,III the level of serum NGAL is compared with the age, duration of smoking (pocket/year), number of attack per year, respiratory function values, serum C reaktive protein (CRP, mg/dL), serum IgE (IU/mL), serum neutrophil (%) and serum lymphocyte (%), blood neutrophil-to-lymphocyte rate and atopy. FINDINGS: In patients having ACO when the maximum level of serum exist, it is observed that serum NGAL level is increased as the number of attacks is increased (p = 0.002). On the other hand in the patients having ACO there was also positive correlation between NLR and serum NGAL level (p < 0.05). There was no other relation found among the other variables. CONCULISION: In the chronic inflamatuar lung diseases the findings of increase in serum NGAL levels while the severity of the disease suggest us serum NGAL levels might be used as a biomarker for evaluating the inflammation.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.